Pfizer Receives European Approval To Expand Use Of prevenar 13 To older children and adolescents aged 6 To 17 years for the prevention of pneumococcal disease
I don't see it being worth much at all. How many adolescents really contract pneumonia. One tiny added use in a single drug for a company Pfizer's size shouldn't move the needle by very much.
However, I see where the stock was up by about 15 cents after hours today as Cramer was waxing very bullish on Pfizer.
About 17 cents, apparently.